Minocin is owned by Rempex.
Minocin contains Minocycline Hydrochloride.
Minocin has a total of 2 drug patents out of which 0 drug patents have expired.
Minocin is available in injectable;injection dosage forms.
Minocin can be used as method of treating bacterial infections.
The generics of Minocin are possible to be released after 12 May, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9084802 | REMPEX | Tetracycline compositions |
May, 2031
(8 years from now) | |
US9278105 | REMPEX | Tetracycline compositions |
May, 2031
(8 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
8
United States
2
Spain
2
Japan
2
New Zealand
2
European Union
1
Israel
1
South Africa
1
Denmark
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Hungary
1
Singapore
1
Colombia
1
Brazil
1
Portugal
1
Korea, Republic of
1
Poland
1
Chile
1
China
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic